Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report

Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzaga-López, A, Muñoz-Rodriguez, J, Ruiz-Casado, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal College of Surgeons 2017
Materias:
Online Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696931/
https://www.ncbi.nlm.nih.gov/pubmed/28768426
http://dx.doi.org/10.1308/rcsann.2017.0143
Descripción
Sumario:Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier’s gangrene.

Ejemplares similares